Abstract
Objective
To explore the epidemiological characteristics of patients with lymphoepithelial carcinoma (LEC) of the head and neck and the prognostic factors.
Methods
We conducted a retrospective cohort study of cases of head and neck LEC retrieved from the Surveillance, Epidemiology and End Results database. Kaplan–Meier survival analysis and the log-rank test were employed to assess overall survival (OS) and cancer-specific survival (CSS). Univariate and multivariate analyses were used to construct Cox regression models. We established nomograms to predict OS and CSS among patients with nasopharyngeal LEC, who were divided into high- and low-risk groups based on the OS nomograms to compare the effects of treatment using the restricted mean survival time (RMST).
Results
The 5-year OS and CSS rates of the cohort were 70.8% and 74.8%, respectively. Advanced age, unmarried status, black race, distant metastasis, and the absence of surgical treatment were significantly associated with decreased survival rates. RMST did not differ between the combined treatment (radiotherapy and chemotherapy) and radiotherapy monotherapy groups, but chemotherapy alone displayed poor efficacy.
Conclusions
Head and neck LEC is associated with a favorable prognosis. Radiotherapy plays a significant role in managing patients with nasopharyngeal LEC, which is influenced by multiple prognostic factors.
Keywords: Lymphoepithelial carcinoma, overall survival, cancer-specific survival, nomogram, restricted mean survival time, radiotherapy, chemotherapy
Introduction
As a rare malignancy, lymphoepithelial carcinoma (LEC) of the head and neck histologically comprises malignant epithelial cells with characteristic lymphoid stroma. Notably, most cases of LEC are related to Epstein–Barr virus infection.1–3 LEC is more common in men than in women, and it predominantly occurs in people aged 50 to 70 years.4–8 Head and neck LEC is a heterogeneous disease with a panoply of clinical manifestations at different onset locations, including the oropharynx, laryngopharynx, and salivary glands.9–11 However, most cases occur in the nasopharynx, and they are classified pathologically as non-keratinizing undifferentiated nasopharyngeal carcinoma.12 In addition, LEC preferentially arises in people of Eskimo, Chinese, and Japanese ethnicity.8 Tobacco smoking and alcohol consumption are considered the potential precipitating factors of LEC.4 The existing literature regarding head and neck LEC mostly consists of case reports and small-scale retrospective analyses, but large-scale population-based studies are rare. Surveillance, Epidemiology, and End Results (SEER), a large-scale tumor registration database in the United States, has accumulated substantial clinical evidence about rare malignant tumors such as LEC. In this study, we retrieved cases of head and neck LEC from the SEER database and reviewed the issues associated with survival and the related prognostic factors.
Materials and methods
Data source and subjects
Because LEC is rare, the research data for this work were extracted from the SEER-9 registry database (1975–2016). We retrieved a substantial number of cases to explore the survival characteristics of patients with LEC. A list of cases diagnosed since 1975, including patients with head and neck LEC, was generated via SEER*Stat version 8.3.8. The primary site of the tumor (Table S1) and histology type (8082/3) were confirmed by the third edition of the International Classification of Disease for Oncology (ICD-O-3). We included patients with confirmed histopathological diagnosis (“positive histology”) and specific order of primary cancer (“one primary only” and “first of two or more primaries”) in the study; however, patients younger than 20 years and those with a follow-up period of 0 months were excluded. For all enrolled individuals, we retrieved information on the following variables: age at diagnosis, sex, marital status, race, year of diagnosis, location of tumor origin, SEER historical stage, grade, surgery, radiotherapy, and chemotherapy. We obtained signed authorization and permission from the SEER database to access and use the data and followed protocols throughout the process to protect patient privacy. Therefore, the requirements for ethics approval and informed consent were waived.
Processes and methods
We applied descriptive statistics to summarize subject characteristics. Through Kaplan–Meier survival analysis, the impact of different factors on overall survival (OS) and cancer-specific survival (CSS) were assessed, followed by the log-rank test for comparison. Hazards ratios (HRs) were generated via Cox regression models for univariate and multivariate analyses in all patients.
Because most included patients had nasopharyngeal LEC (72.9%) in our study, the least absolute shrinkage and selection operator (LASSO) regression model13 and Cox multivariate regression analysis were employed to select the characteristic prognosis factors for such patients. Thereafter, we devised a nomogram model to predict 1-, 3-, and 5-year OS and CSS. Calibration curves were applied to assess the predictive accuracy of the nomogram. Patients were categorized into high- and low-risk groups based on the risk scores of the nomogram. Subsequently, the Cox regression model and restricted mean survival time (RMST) model were established to evaluate the mortality risks of the two risk groups. Moreover, we applied the RMST model to assess the effects of combined radiotherapy and chemotherapy, chemotherapy alone, and radiotherapy alone in patients in different risk groups.
Statistical analysis
Basic descriptive statistical analysis was performed via Stata version 14.0 (Stata Corporation, College Station, TX, USA). For other analyses, Rstudio version 4.0.2 was adopted. The associated software packages included “survminer,” “rms,” “ggplot,” “glmnet,” “nomogramEx,” and “survRM2.” Statistical significance was set at P < 0.05 on both sides.
Results
Characteristics of the study subjects
In total, 1398 patients with head and neck LEC (mean age, 51.8 ± 14.6 years; median age, 52 years) were enrolled in the study. Most patients were male (974, 69.7%). Notably, a higher proportion of patients (70.4%) were enrolled after 1995. Detailed patient characteristics are presented in Table 1.
Table 1.
Baseline demographic and clinicopathologic characteristics of lymphoepithelial carcinoma diagnosed in SEER 9 registries (1975–2016).
| Characteristic | No. of patients | % |
|---|---|---|
| Total | 1398 | 100 |
| Age at diagnosis (years) | ||
| Mean ± SD | 51.8 (14.6) | |
| Median (IQR) | 52 (42–62) | |
| 20–39 | 269 | 19.2 |
| 40–59 | 718 | 51.4 |
| 60–79 | 367 | 26.3 |
| ≥80 | 44 | 3.1 |
| Sex | ||
| Female | 424 | 30.3 |
| Male | 974 | 69.7 |
| Marital status | ||
| Married | 916 | 65.5 |
| Unmarried | 407 | 29.1 |
| Race | ||
| White | 702 | 50.2 |
| Black | 110 | 7.9 |
| Asian or Pacific Islander | 543 | 38.8 |
| Year of diagnosis | ||
| 1975–1984 | 218 | 15.6 |
| 1985–1994 | 196 | 14 |
| 1995–2004 | 513 | 36.7 |
| 2005–2016 | 471 | 33.7 |
| Primary site | ||
| Oral cavity | 65 | 4.6 |
| Salivary glands | 146 | 10.4 |
| Oropharynx | 149 | 10.7 |
| Nasopharynx | 1019 | 72.9 |
| Larynx, glottis, and hypopharynx | 19 | 1.4 |
| SEER historical stage | ||
| Localized | 171 | 12.2 |
| Regional | 716 | 51.2 |
| Distant | 114 | 8.2 |
| Grade | ||
| Low | 12 | 0.9 |
| High | 937 | 67 |
| Surgery | ||
| Yes | 462 | 33 |
| No | 912 | 65.2 |
| Radiation and chemotherapy | ||
| Both | 725 | 51.9 |
| Radiation only | 505 | 36.1 |
| Chemotherapy only | 47 | 3.4 |
| No/unknown | 121 | 8.7 |
| Cancer-specific mortality | ||
| Alive | 918 | 65.7 |
| Dead | 480 | 34.3 |
| Overall survival | ||
| Alive | 677 | 48.4 |
| Dead | 721 | 51.6 |
| Survival time (months) | ||
| Mean ± SD | 111.2 (93.0) | |
| Median (IQR) | 91 (33–163) | |
SD, standard deviation; IQR, interquartile range.
The demographic and survival characteristics of patients with head and neck LEC according to the primary tumor location are summarized in Table S2. Nearly 72.9% of patients had LEC of the nasopharynx, and the mean age of these patients (49 years) was lower than that of patients with other tumor locations. Excluding LEC of the salivary glands, more patients were male than female for each tumor location. Patients with LEC of the larynx, glottis, and hypopharynx were characterized by the lowest 5-year OS (52.0%) and 5-year CSS (66.8%).
Survival analysis
The OS and CSS data for all patients with LEC of the head and neck are highlighted in Figure 1a and 1b, respectively. At the end of follow-up, 721 patients had died, 480 of whom succumbed to cancer-related diseases. According to Kaplan–Meier survival analysis, the median OS was 156 months, and the 5-year OS rate was 70.8%. Of note, OS was superior to CSS in all patients.
Figure 1.
Survival analysis of lymphoepithelial carcinoma: (a) OS and (b) CSS are presented for all patients OS and CSS analysis stratified by age (c, d) and sex (e, f).
OS, overall survival; CSS, cancer-specific survival.
For subgroup analyses, we created Kaplan–Meier survival curves to compare OS and CSS (Figures 1 and S1–2). Older age was associated with worse OS and CSS. Men displayed significantly worse OS and CSS than women. White race and a married status were identified as favorable prognostic factors. Compared with patients diagnosed between 1975 and 1984, patients diagnosed after 1984 had significantly better OS and CSS (both P < 0.0001). The dismal OS and CSS of patients diagnosed before 1985 were associated with distant metastases or high-grade malignancy.
Regarding treatment (Figure S3), patients who underwent surgery or received simultaneous radiotherapy and chemotherapy exhibited longer OS and CSS than those who declined surgery or received a single treatment (radiotherapy or chemotherapy alone).
Cox multivariate regression models for all patients
To generate the Cox multivariate regression models for OS and CSS, we selected variables significant at P < 0.05 in Cox univariate regression models (Table S3). As presented in Table 2, older age was associated with worse OS (e.g., ≥80: HR = 6.58, 95% confidence interval [CI] = 3.09–14.00) and CSS (e.g., ≥80: HR = 2.56, 95% CI = 0.84–7.82). Unmarried patients had 1.44- (OS) and 1.60-fold (CSS) higher risks of mortality than married patients, and the increased risks were statistically significant (both P < 0.05). Black patients had worse OS (HR = 2.19, 95% CI = 1.41–3.38) and CSS (HR = 2.36, 95% CI = 1.42–3.93) than white patients. Furthermore, the year of diagnosis, distant metastasis, and the receipt of surgery significantly impacted OS and CSS (all P < 0.05).
Table 2.
Cox multivariate regression analysis of prognostic factors for OS and CSS among patients with lymphoepithelial carcinoma of the head and neck.
|
*P < 0.05, **P < 0.01.
Nomograms for nasopharyngeal LEC
Because the majority of patients had nasopharyngeal LEC (72.9%), we established nomograms for clinical prediction. Using the LASSO regression model, we screened variables for predicting OS and CSS and solved the over-fitting problem caused by multicollinearity (Table S4). Notably, Yes, the operation for each characteristic provided a different result depending on the software; thus, we set the operation to repeat 1000 times to calculate the frequency of each variable. Subsequently, the selected characteristic variables with high frequencies (>800) were integrated into Cox multivariate regression models (Table S5).
The clinical prediction models for 1-, 3-, and 5-year OS and CSS (Figure 2) were constructed according to the critical predictor variables selected via LASSO regression. To evaluate the accuracy of the nomograms, we used new samples generated from bootstrap self-sampling. Theoretically, the standard calibration curve is a straight line passing the origin of the coordinate axis with a slope of 1. Of note, the predictive power of the line graph increases as the prediction calibration curve gets closer to the standard curve. The nomograms predicting 1-, 3-, and 5-year OS and CSS exhibited a reasonable fit with predictive ability (Figure 3).
Figure 2.
Nomograms predicting OS (a) and CSS (b) among patients with nasopharyngeal lymphoepithelial carcinoma.
OS, overall survival; CSS, cancer-specific survival.
Figure 3.
Calibration plots for the nomogram. (a–c) 1-, 3-, and 5-year OS and (d–f) 1-, 3-, and 5-year CSS
OS, overall survival; CSS, cancer-specific survival.
Patients with LEC of the nasopharynx were grouped into high- and low-risk groups. This classification was based on the median overall score for all patients calculated from the variable scores in the OS nomogram. Using the low-risk group as a reference in the Cox regression model, the high-risk group had a 2.06-fold (95% CI = 1.59–2.67) higher risk of death. Then, we applied RMST to compare the mean survival time of the two risk groups up to a specific time. Notably, RMST could be estimated as the area under the survival curve up to the predetermined time point; therefore, we considered all survival information during this time range. In the RMST analysis, three different time points (1, 3, and 5 years) were selected to calculate the corresponding results. Of note, the average survival time of the high-risk group at specified times was significantly lower than that of the low-risk group (P < 0.05, Table S6).
We also compared RMST in different risk groups according to the treatment method (Figures 4 and 5). Based on the results, the effects of combined radiotherapy and chemotherapy and radiotherapy alone on RMST did not significantly differ between different risk groups at different time points. Compared with the effects of combined chemotherapy and radiotherapy, chemotherapy alone was associated with significantly worse survival.
Figure 4.
Comparison of the effects of combined radiotherapy and chemotherapy and radiotherapy alone on 1-, 3- and 5-year RMST among patients with nasopharyngeal lymphoepithelial carcinoma in different risk groups.
RMST, restricted mean survival time.
Figure 5.
Comparison of the effects of combined radiotherapy and chemotherapy and chemotherapy alone on 1-, 3-, and 5-year RMST among patients with nasopharyngeal lymphoepithelial carcinoma in different risk groups.
RMST, restricted mean survival time.
Discussion
As a rare disease, LEC poses challenges to epidemiological research, particularly regarding the collection of a reliable number of clinical cases for exploration. To our knowledge, the case data we extracted from the SEER database represent the largest sample size of all existing studies; thus, these data were comprehensively used to explore the survival and prognostic factors of LEC.
In the present study, the median age of all patients at diagnosis was 52 years. Excluding patients with nasopharyngeal LEC (median age, 49 years), patients with different sites of disease onset were older, in line with the findings of previous studies.14–16 Excluding LEC of the salivary glands, other sites of disease onset displayed higher incidence rates in men. Salivary gland LEC, in particular parotid gland LEC, is more common in women, and it most frequently occurs in the fourth to fifth decades of life.17 To eliminate disparities, clarification of the impact of sex requires further research in specific cancers. The results of survival analysis demonstrated the association of advanced age with poor OS and CSS, which might be related to their physical condition and tolerance to treatment. Patients diagnosed after 1984 had significantly better OS and CSS. By searching the literature, we found that treatment techniques have gradually changed. Originally, radiotherapy was the main treatment, and it was linked to high rates of locoregional tumor control. After 1985, clinical trials of radiotherapy combined with chemotherapy were gradually reported.18–21 In the meantime, the methods of radiotherapy have been further improved, and radiation techniques have been perfected.22,23 In addition, patient compliance and the rate of diagnosis might be additional factors. The prognosis of LEC of the larynx, glottis, and hypopharynx appears to be significantly worse, and this could have several explanations. First, diagnosis can be challenging because the tumors arise from submucosal sites, and because of the small number of cases, there is no clear reference for diagnostic criteria. Second, many patients had histologically confirmed cervical lymph node metastasis at the time of diagnosis as well as systemic metastases. Third, treatments are not standard, and the dose of radiation is still being explored. Most patients die of distant metastasis, but surgery and adjuvant chemotherapy do not effectively prevent metastasis.
Numerous studies have demonstrated racial differences in the incidence of LEC; overall, laryngeal and hypo pharyngeal LEC are more prevalent in whites than in Asians,24 and people of Eskimo/Inuit ethnicity experience higher rates of LEC in the salivary glands.25,26 In this study, we identified black race as a risk factor for head and neck LEC regardless of OS or CSS. The ethnic and genetic background might affect the pathogenesis of LEC, or differences in exposure factors of LEC-related etiology could arise among people in different regions.
Local spread or nodal metastases are fairly common at the time of diagnosis. Thus, establishing timely and scientific treatment management strategies is undeniably essential. Common treatment approaches include surgical resection, neck dissection, radiotherapy, chemotherapy, and combinations of several approaches. In most cases, LEC occurs in the nasal cavity, and it is morphologically similar to non-keratinizing undifferentiated nasopharyngeal carcinoma.27 Radiotherapy is preferable because of the radiosensitivity of nasopharyngeal carcinoma.28 This recommendation has been validated by our findings. Non-nasopharyngeal LEC is rare, and its clinical behavior and treatment responsiveness are not fully understood. The major management strategies for laryngeal and hypopharyngeal LEC is surgery and radiotherapy.29 For salivary LEC, it is often difficult to completely remove the tumor because of the presence of facial nerves, and thus, postoperative radiotherapy has been a significant adjuvant treatment after surgery.30 Based on our knowledge, data on the treatment of non-nasopharyngeal LEC are limited. Overall, favorable prognoses were evident regarding the efficacy responses in clinical treatment.
Nomograms have been used in clinical prediction research.31–33 In this study, we established nomograms to predict 1-, 3-, and 5-year OS and CSS for patients with nasopharyngeal LEC. The nomograms were validated to determine the degree of model fit and the applicability of prediction. We categorized patients into high- and low-risk groups, which allowed us to compare their corresponding treatments according to the nomogram scores. The established nomograms could accurately predict the patients’ individual survival probabilities and formulate a reasonable follow-up time schedule, which significantly improved clinical practice.
This study had some limitations. First, being a retrospective study, some subjectivity is inevitable. Second, the SEER database might lack important information such as related virus detection and detailed treatment plans, which could have resulted in insufficient discussion of the relevant issues. Third, because of the rarity of the disease, the period of study enrollment was relatively large, which allowed us to better explore the survival characteristics. During this period, the staging methods and diagnosis varied over time. However, we used the SEER historical staging and year classification to partially solve this problem. Notwithstanding these shortcomings, this large population study provided valuable reference materials for this rare disease. Thus, our study is applicable to current research on LEC.
Conclusion
The present study affirmed that head and neck LEC is a rare disease, and advanced age, an unmarried status, and distant metastasis were associated with a higher risk. Compared with the effects of chemotherapy, radiotherapy has a more significant role in the treatment of LEC.
Supplemental Material
Supplemental material, sj-pdf-1-imr-10.1177_03000605221148895 for Lymphoepithelial carcinoma of the head and neck: a SEER analysis of prognostic factors for survival by Jing Wei, Hui Deng, Lihua Wu, Jianbo Song, Junping Zhang, Wenhui Yang, Mengxian Zhang and Hongtao Zhen in Journal of International Medical Research
Authors’ contributions: Hongtao Zhen conceived the study idea and critically revised the manuscript. Hui Deng and Jing Wei reviewed the literature, analyzed the data, and drafted the manuscript. Lihua Wu, Jianbo Song, Junping Zhang, Wenhui Yang, and Mengxian Zhang contributed to study design. All authors read and approved the final version of the manuscript as submitted and agreed to be held accountable for all aspects of the work.
The authors declare that there is no conflict of interest.
Funding: We received no external funding for this study. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
ORCID iD: Hui Deng https://orcid.org/0000-0002-3330-3935
Data availability statement
We analyzed publicly available data sets. These data are available in the SEER database (https://seer.cancer.gov/).
References
- 1.Faisal M, Hartenbach S, Schratter A, et al. Lymphoepithelial carcinoma of larynx and hypopharynx: a rare clinicopathological entity. Cancers (Basel) 2020; 12: 2431. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Kim YJ, Hong HS, Jeong SH, et al. Lymphoepithelial carcinoma of the salivary glands. Medicine (Baltimore) 2017; 96: e6115. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Zong Y, Liu K, Zhong B, et al. Epstein-Barr virus infection of sinonasal lymphoepithelial carcinoma in Guangzhou. Chin Med J (Engl) 2001; 114: 132–136. [PubMed] [Google Scholar]
- 4.Acuña G, Gomà M, Temprana-Salvador J, et al. Human papillomavirus in laryngeal and hypopharyngeal lymphoepithelial carcinoma. Mod Pathol 2019; 32: 621–626. [DOI] [PubMed] [Google Scholar]
- 5.Takakura H, Tachino H, Fujisaka M, et al. Lymphoepithelial carcinoma of the maxillary sinus: A case report and review of the literature. Medicine (Baltimore) 2018; 97: e11371. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Wang P, Yang J, Yu Q. Lymphoepithelial carcinoma of salivary glands: CT and MR imaging findings. Dentomaxillofac Radiol 2017; 46: 20170053. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Ferlito A, Devaney KO, Hunt JL, et al. Some Considerations on the WHO Histological Classification of Laryngeal Neoplasms. Adv Ther 2019; 36: 1511–1517. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Schneider M, Rizzardi C. Lymphoepithelial carcinoma of the parotid glands and its relationship with benign lymphoepithelial lesions. Arch Pathol Lab Med 2008; 132: 278–282. [DOI] [PubMed] [Google Scholar]
- 9.Sckolnick J, Murphy J, Hunt JL. Microsatellite instability in nasopharyngeal and lymphoepithelial carcinomas of the head and neck. Am J Surg Pathol 2006; 30: 1250–1253. [DOI] [PubMed] [Google Scholar]
- 10.MacMillan C, Kapadia SB, Finkelstein SD, et al. Lymphoepithelial carcinoma of the larynx and hypopharynx: study of eight cases with relationship to Epstein-Barr virus and p53 gene alterations, and review of the literature. Hum Pathol 1996; 27: 1172–1179. [DOI] [PubMed] [Google Scholar]
- 11.Wang CP, Chang YL, Ko JY, et al. Lymphoepithelial carcinoma versus large cell undifferentiated carcinoma of the major salivary glands. Cancer 2004; 101: 2020–2027. [DOI] [PubMed] [Google Scholar]
- 12.Wenig BM. Lymphoepithelial-like carcinomas of the head and neck. Semin Diagn Pathol 2015; 32: 74–86. [DOI] [PubMed] [Google Scholar]
- 13.Zhou ZR, Wang WW, Li Y, et al. In-depth mining of clinical data: the construction of clinical prediction model with R. Ann Transl Med 2019; 7: 796. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Rytkönen AE, Hirvikoski PP, Salo TA. Lymphoepithelial carcinoma: two case reports and a systematic review of oral and sinonasal cases. Head Neck Pathol 2011; 5: 327–334. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Zhan KY, Nicolli EA, Khaja SF, et al. Lymphoepithelial carcinoma of the major salivary glands: Predictors of survival in a non-endemic region. Oral Oncol 2016; 52: 24–29. [DOI] [PubMed] [Google Scholar]
- 16.Carpenter DH, El-Mofty SK, Lewis JS., Jr. Undifferentiated carcinoma of the oropharynx: a human papillomavirus-associated tumor with a favorable prognosis. Mod Pathol 2011; 24: 1306–1312. [DOI] [PubMed] [Google Scholar]
- 17.Wang P, Yang J, Yu Q. Lymphoepithelial carcinoma of salivary glands: CT and MR imaging findings. Dentomaxillofac Radiol 2017; 46: 20170053. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Azli N, Fandi A, Bachouchi M, et al. Final report of a phase II study of chemotherapy with bleomycin, epirubicin, and cisplatin for locally advanced and metastatic/recurrent undifferentiated carcinoma of the nasopharyngeal type. Cancer J Sci Am 1995; 1: 222–229. [PubMed] [Google Scholar]
- 19.Pendjer I, Krejovic B, Vucicevic S. A comparative study of undifferentiated nasopharyngeal carcinoma treated with radiotherapy or combined treatment with zorubicin-cisplatin and radiotherapy. Eur Arch Otorhinolaryngol 1997; 254: S127–S129. [DOI] [PubMed] [Google Scholar]
- 20.Taamma A, Fandi A, Azli N, et al. Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type. Cancer 1999; 86: 1101–1108. [DOI] [PubMed] [Google Scholar]
- 21.Benasso M, Sanguineti G, D'Amico M, et al. Induction chemotherapy followed by alternating chemo-radiotherapy in stage IV undifferentiated nasopharyngeal carcinoma. Br J Cancer 2000; 83: 1437–1442. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 2002; 53: 12–22. [DOI] [PubMed] [Google Scholar]
- 23.Pow EH, Kwong DL, McMillan AS, et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 2006; 66: 981–991. [DOI] [PubMed] [Google Scholar]
- 24.Marioni G, Mariuzzi L, Gaio E, et al. Lymphoepithelial carcinoma of the larynx. Acta Otolaryngol 2002; 122: 429–434. [DOI] [PubMed] [Google Scholar]
- 25.Kennedy RA. WHO is in and WHO is out of the mouth, salivary glands, and jaws sections of the 4th edition of the WHO classification of head and neck tumours. Br J Oral Maxillofac Surg 2018; 56: 90–95. [DOI] [PubMed] [Google Scholar]
- 26.Silvers AR, Som PM. Salivary glands. Radiol Clin North Am 1998; 36: 941–966vi. [DOI] [PubMed] [Google Scholar]
- 27.Jeng YM, Sung MT, Fang CL, et al. Sinonasal undifferentiated carcinoma and nasopharyngeal-type undifferentiated carcinoma: two clinically, biologically, and histopathologically distinct entities. Am J Surg Pathol 2002; 26: 371–376. [DOI] [PubMed] [Google Scholar]
- 28.Manganaris A, Patakiouta F, Xirou P, et al. Lymphoepithelial carcinoma of the parotid gland: is an association with Epstein-Barr virus possible in non-endemic areas? Int J Oral Maxillofac Surg 2007; 36: 556–559. [DOI] [PubMed] [Google Scholar]
- 29.Chen YP, Chan ATC, Le QT, et al. Nasopharyngeal carcinoma. Lancet 2019; 394: 64–80. [DOI] [PubMed] [Google Scholar]
- 30.Thompson LDR, Whaley RD. Lymphoepithelial Carcinoma of Salivary Glands. Surg Pathol Clin 2021; 14: 75–96. [DOI] [PubMed] [Google Scholar]
- 31.Zhang SL, Chen C, Rao QW, et al. Incidence, prognostic factors and survival outcome in Patients with primary hepatic lymphoma. Front Oncol 2020; 10: 750. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.He Y, Zhu Z, Chen Y, et al. Development and Validation of a Novel Diagnostic Nomogram to Differentiate Between Intestinal Tuberculosis and Crohn's Disease: A 6-year Prospective Multicenter Study. Am J Gastroenterol 2019; 114: 490–499. [DOI] [PubMed] [Google Scholar]
- 33.Cui J, Wen Q, Tan X, et al. An integrated nomogram combining lncRNAs classifier and clinicopathologic factors to predict the recurrence of head and neck squamous cell carcinoma. Sci Rep 2019; 9: 17460. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Supplemental material, sj-pdf-1-imr-10.1177_03000605221148895 for Lymphoepithelial carcinoma of the head and neck: a SEER analysis of prognostic factors for survival by Jing Wei, Hui Deng, Lihua Wu, Jianbo Song, Junping Zhang, Wenhui Yang, Mengxian Zhang and Hongtao Zhen in Journal of International Medical Research
Data Availability Statement
We analyzed publicly available data sets. These data are available in the SEER database (https://seer.cancer.gov/).





